Pathologic Complete Response to Neoadjuvant Nivolumab/Ipilimumab in a Patient with Metastatic Renal Cell Carcinoma. (2nd November 2020)

• Record Type: Journal Article
• Authors: Peak, Taylor C.; Fenu, Elena M.; Rothberg, Michael B.; Thomas, Christopher Y.; Davis, Ronald L.; Levine, Edward A.
• Other Names: Goel Apul Academic Editor.
• Is Part Of: Case reports in urology. Volume 2020(2020)
• Publication Date: 2020-11-02
• Subjects: Urology -- Periodicals; Urology -- Case studies -- Periodicals; Genitourinary organs -- Diseases -- Periodicals; Urologic Diseases; Genitourinary organs -- Diseases; Urology; Periodicals; Case studies; Periodicals; 616.6005
• DOI: 10.1155/2020/8846135
• Languages: English
• ISSNs: 2090-696X

Abstract

Abstract : Nivolumab plus ipilimumab represents an effective combination of checkpoint inhibitors that can lead to a durable response with minimal toxicity in patients with metastatic renal cell carcinoma (mRCC). We present a case of a pathologic complete response to neoadjuvant nivolumab plus ipilimumab in a patient with a 13.9 cm left renal mass and significant retroperitoneal and iliac lymphadenopathy, classified as intermediate-risk mRCC. We discuss and review the literature on complete responses after systemic therapy and the ability to predict who has undergone a complete response in the face of residual radiographic evidence of disease.